Cabaletta Bio Business Summary

Cabaletta Bio, Inc. (CABA) is a late-stage clinical biotechnology company specializing in the development of engineered T cell therapies for B cell-mediated autoimmune diseases. Operating as a pre-revenue biopharmaceutical entity, the company’s business model is centered on the eventual commercialization of proprietary therapies and potential strategic licensing or co-development partnerships. Its primary business segments are divided into two technology platforms: CARTA (Chimeric Antigen Receptor T cells for Autoimmunity), led by its flagship candidate rese-cel (CABA-201), and CAART (Chimeric AutoAntibody Receptor T cells), which targets specific pathogenic B cells while sparing healthy ones. As of early 2026, Cabaletta is advancing a pivotal registrational cohort in myositis with a planned BLA submission for 2027, supported by a strategic manufacturing partnership with Cellares to utilize the automated Cell Shuttle platform. The company competes directly with Kyverna Therapeutics, Cartesian Therapeutics, and Bristol Myers Squibb in the autoimmune CAR-T space, positioning itself as a precision-focused leader aiming for curative, drug-free remission through deep B cell depletion and immune system resetting. The leadership team is anchored by Co-founder, President, and CEO Steven Nichtberger, M.D., a former Merck executive and Wharton adjunct professor, alongside Co-founders Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., whose foundational research at the University of Pennsylvania drives the company's IP. Key executives include Chief Scientific Officer Samik Basu, M.D., President of Science and Technology Gwendolyn Binder, Ph.D. (formerly of Adaptimmune), and Chief Technology Officer Sarah Yuan, Ph.D., who joined in 2024 to oversee CMC and manufacturing scale-up. In 2025, the team was further strengthened by Chief Commercial Officer Steve Gavel, a veteran of Legend Biotech who led the launch of Carvykti. The company is backed by a robust institutional investor base including T. Rowe Price, Alyeska Investment Group, and Vanguard, with a board of directors featuring notable industry figures such as Catherine Bollard, M.D., and former AbbVie executive Scott Brun, M.D.